Survey checks if doctors heed drug warnings
NCT ID NCT06714448
Summary
This study is a survey to check if doctors and pharmacists in Saudi Arabia are aware of and following important safety warnings for the epilepsy drug Depakine (sodium valproate). It involves 3,500 healthcare professionals who prescribe or dispense the medication. No treatments are given; researchers are only gathering information through questionnaires.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
Conditions
Explore the condition pages connected to this study.